with PPBL in comparison with 6 control samples from healthy donors (4 individuals and 2 pools (12 donors each)). PPBL patients (10 women, 4 men) had a median age of 43 (range 28-63). All were smokers with an average lymphocyte count of 5.34 Â 10 7 per ml (range 3.7-9). Individual patient details are given in Supplementary Table S1 . Total RNA (100 ng), purified from Trizol, was amplified and labelled using the one-cycle method and hybridized to GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA, USA) as recommended by the manufacturers.
After first removing genes of low signal intensity (o50), unsupervised analysis resolved normal and PPBL samples according to gene expression levels (Supplementary Figure  S1a) . ANOVA was used to identify 7054 differentially expressed genes between PPBL and controls (Po0.05; Benjamini and Hochberg corrected), 2001 of which were downregulated and 651 genes upregulated by more than twofold (Supplementary Figure S1b) . The top 30 upregulated and downregulated genes are shown in Supplementary Tables S2 and S3 . The use of these 60 genes in a leave-one-out cross-validation model (K-nearest neighbour method) resulted in 100% correct discrimination between PPBL and control samples. Indeed using only two of the top up-and downregulated genes (ID2, ANX1, P2RY14, SCN3A) resulted in correct prediction for all samples. In order to see whether these genes could also differentiate PPBL from chronic lymphocytic leukaemia (CLL), we downloaded publicly available microarray data from a series of 20 CLL patients (GEO dataset: GSE9250). The four genes were able to correctly predict 18/20 of CLL cases from PPBL and control samples (37/39 (95%)). Additionally, cluster analyses using either the 60-gene or the 4-gene signature were able to distinguish PPBL, CLL and control samples (Supplementary Figures S2a and S2b, respectively).
Four of the most highly upregulated genes (Fos, FosB, Jun and JunB) are components of the activator protein-1 (AP-1) transcription complex. Indeed levels of Jun, JunB and Fos in some PPBL samples measured by qRT-PCR were more than 100 times higher than healthy control samples (Figure 1a-e) . Immunohistochemical staining confirmed high protein levels of JunB and Fos (Figure 2a) , strongly suggesting that AP-1 is constitutively expressed in PPBL.
The AP-1 transcription complex is a heterodimer composed of members of the Fos family (c-Fos, FosB, Fra-1 and Fra-2) and the Jun family (c-Jun, JunB and JunD). 2 In addition, some Maf family members, including Maff and Mafb, also amongst the top 30 upregulated genes in PPBL, can also dimerize with c-Fos. Members of the complex are highly oncogenic and deregulation of AP-1 activity alone appears to be sufficient for neoplastic transformation (reviewed by Ozanne et al.
2 ). In lymphomas, constitutive expression of AP-1 is characteristic of CD30 þ malignancies, including Hodgkin's lymphoma (HL) and anaplastic large cell lymphoma (ALCL) where CD30 and JunB expression have been shown to upregulate each other. 3 Like HL and ALCL cell lines, 3 treatment of PPBL cell lines with the MEK1/2 inhibitor, but not p38-MAPK or JNK inhibitors, caused inhibition of JunB expression (Figure 2b ) and ERK1/2 MAPK phosphorylation ( Figure 2c ). As PPBL cells were also found to CD30 þ by immunohistochemical staining (Figure 2a ), this suggests that constitutive expression of AP-1 in PPBL follows a similar, if not identical, pathway to that observed in HL and ALCL. This is as far as we are aware the first report of constitutive AP-1 expression in non-malignant disease.
Willenbrock et al. 4 suggested that as well as sharing pathophisological features HL and ALCL also express common genes, and identified 10 upregulated and 32 downregulated genes that distinguished these malignancies from other lymphoma types and normal lymphocyte samples. We found a striking similarity in expression levels of these genes in PPBL patient samples (Supplementary Table S4 ); all the 10 upregulated genes were also upregulated in PPBL (7/10 Po0.05) and 28/32 (88%) downregulated genes in HL and ALCL were also downregulated in PPBL (23/28 Po0.05). This further suggests that that constitutive AP-1 expression drives a common gene expression signature in PPBL, HL and ALCL.
The action of AP-1, in part due to its heterodimeric nature, is complex and in the wealth of literature available often appears contradictory and highly context specific, for example it is clearly pro-apoptotic in certain cell types and prosurvival in others. Consequently the role constitutive AP-1 expression plays in the pathogenesis of PPBL or indeed cancer remains unclear.
In contrast, a clear link with the anti-apoptotic phenotype of PPBL was suggested by pathway analysis of the microarray data, as components of the death-receptor (Fas/Fas-L) apoptotic signalling pathway were found to be downregulated (Supplementary Table S5 and Figure S3 ). FADD downregulation (Figure 1f ; P ¼ 0.02) has also been reported in mantle cell lymphoma. These data are consistent with our previous findings as PPBL cells underwent apoptosis following etoposide treatment but were resistant to anti-Fas antibody treatment. 5 Other pro-apoptotic molecules that were downregulated in PPBL samples include STK17A (Figure 1g ; P ¼ 0.001) and BACH2 (Figure 1h ; P ¼ 0.0007). STK17A was recently found to be commonly downregulated in non-Hodgkin's lymphoma. BACH2 is a B-cell specific transcription factor that induces apoptosis in lymphoma cells and reduced expression has been associated with poor prognostic outcome in diffuse large B-cell lymphoma. 7 Our data also suggested that many components of the transforming growth factor-b (TGFb) signalling pathway are downregulated in PPBL (Supplementary Figure S3) , including the tumour-suppressor molecule SMAD4 (Figure 1i ; P ¼ 0.007). The TGFb pathway negatively regulates cell growth, and inactivation of SMAD4 is present in over half of pancreatic cancers and up to 35% of colorectal cancers. 8 This is as far as we know the first description of the downregulation of SMAD4 in a B-cell disorder.
PPBL represents a useful model for B-cell dysfunction as it displays characteristics associated with benign (polyclonality, benign clinical course) and malignant disease (frequent chromosomal abnormalities and aberrant B-cell morphology). Nearly all studies to date have sought to characterize the morphological or genetic features of this disorder. This study represents not only the first detailed molecular investigation of PPBL, but also includes a large proportion of all documented (o100) cases. Taken together these data suggest that PPBL although a benign disorder appears to share many molecular features of malignancy that can used to further our understanding of haematological disease and clearly warrant further research. The nuclear factor I (NFI) family of transcription factors comprises four members in humans, NFIA, NFIB, NFIC and NFIX, which are involved in various cellular processes. 1 The NFI proteins comprise a DNA binding and dimerization domain in their N-terminal half, which contains four cysteine residues common to the four vertebrate members and conserved in the nonvertebrate orthologs, and a transactivation and repression domain in their C-terminal half (Figure 1a) . The NFIA gene, located in the 1p31 chromosomal region, has a function in brain, [2] [3] [4] ureteral and renal development 3 as well as hematopoiesis. 5, 6 Interactions of NFIA with CEBPa and PU.1 through microRNAs regulate granulocytic and monocytic differentiation, respectively. 5, 6 NFIA regulates erythropoiesis through a network involving NR2C1, GATA1 and erythropoietin. [7] [8] [9] To determine whether NFIA could have a function in early leukemogenesis, we searched for alterations of the NFIA gene in 89 chronic hematopoietic diseases by using array-comparative genomic hybridization (aCGH) and DNA sequencing. Our series comprised 35 chronic myelomonocytic leukemias and 54 myeloproliferative disorders including 8 cases of polycythemia vera (PV), 42 cases of essential thrombocythemia and 4 cases of idiopathic myelofibrosis. The aCGH experiments used high-density oligonucleotide microarrays (Hu-244A, Agilent Technologies, Massy, France) as previously described.
10 aCGH was done on 84 samples. We sequenced exons 2-11 of the gene for 48 samples (all chronic myelomonocytic leukemia, 5 essential thrombocythemia and 8 PV), and only exon 2 for the remaining 41 myeloproliferative disorder samples (primers are available on demand).
We found alterations of the NFIA gene in two patients, mentioned here as patients 1 and 2.
Patient 1, a 56-year-old woman, presented with erythrocytosis and thrombocytosis in 2003. Bone marrow examination showed
